08Jan
The New Exclusive European Licensee of Cenobamate: Angelini Pharma Acquires Emerging Swiss Biotech Company Arvelle Therapeutics
The Italian pharmaceutical company Angelini Pharma announced on January 4, 2021, that it will acquire emerging Swiss biotech company Arvelle Therapeutics for a total aggregate valuation of up to $960 million. Angelini Pharma will pay Arvelle Therapeutics $610 million following the European Medicines Agency’s (“EMA”) approval of the epilepsy drug cenobamate, sold under the brand name Xcopri®. Arvelle will also receive another $350 million if cenobamate reaches certain revenue targets....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
You’ve got a lot on your plate as a retirement plan provider and the last thing you need is more he...
Read More >
Ohio local hiring laws affecting contractors are destroyed, for now. Municipalities will no longer ...
Read More >
Although there is no standard set of measures that a company can implement to guarantee that it will...
Read More >
The Federal Motor Carrier Safety Administration (FMCSA) has announced a notice of proposed rulemakin...
Read More >
ERISA requires Summary Plan Descriptions and other disclosures to be "written in a manner calculated...
Read More >
Nicholas Honchariw’s battles with the County of Stanislaus over his 9-lot subdivision have now resu...
Read More >